Skip to content
Logo of the Deater Foundation, Inc.
Deater Foundation, Inc.
Dedicated to funding HSAN1 research to find a treatment and cure.
  • About
    • DFI’s Mission
    • About HSAN1
    • Year In Review
    • HSAN1’s Cause
    • The Deater Family
  • HSAN1 Registry
  • Funding
  • Photo Gallery
  • Research
    • DFI Timeline/History
    • Newsletter Archive
    • Related Articles
    • MGH Symposiums
    • Additional Info
    • Related Links
  • Posts
    • Blog Posts by Category
  • Products & Tips
  • Contact

Related Articles

  • Gantner et al. (2019) “Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy” The New England Journal of Medicine.
    • Supplemental Index
  • Tyynismaa (2019) “A Metabolic Vulnerability of Vision” The New England Journal of Medicine
  • Fridman, Vera et al. (2019) “Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1.” Neurology 92.4 (2019): e359-e370. Web. 21 Jan. 2019.
  • Harrison, Dunn & Campopiano (2018) – Sphingolipid biosynthesis in man and microbes
  • Ernst et al. (2015) – Novel HSAN1 Mutation in Serine Palmitoyltransferase Resides at a Putative Phosphorylation Site That is Involved in Regulating Substrate Specificity
  • Othman et al. (2015) – Lowering Plasma 1-Deoxysphingolipids Improves Neuropathy in Diabetic Rats
  • ResearchFridman et al. (2015) – Natural History and Biomarkers in Hereditary Sensory Neuropathy Type 1
  • Myers et al. (2014) – Mutations in the SPTLC1 Protein Cause Mitochondrial Structural Abnormalities and Endoplasmic Reticulum Stress in Lymphoblasts
  • Suh et al. (2014) – Early-Onset Severe Hereditary Sensory and Autonomic Neuropathy Type 1 with S331F SPTLC1 Mutation
  • Murphy et al. (2013) – HSAN1 Caused by a Novel Mutation in SPTLC2
  • Auer-Grumbach et al. (2013) – Mutations at Ser331 in the HSN Type I Gene SPTLC1 are Associated with a Distinct Syndromic Phenotype
  • Garofolo et al. (2011) – Oral L-serine supplementation reduces production of neurotoxic dSLs in mice and humans with HSAN1
  • Scherer et al. (2011) – The Debut of a Rational Treatment for an Inherited Neuropathy?
  • Rotthier et al. (2011) – Characterization of Two Mutations in SPTLC1 Subunit of SPT Associated with HSAN1
  • Rotthier et al. (2010) – Mutations in the SPTLC2 Subunit of SPT Cause HSAN1
  • Bertea et al. (2010) – DSBs as Plasma Markers in Diabetes Mellitus
  • Penno et al. (2010) – HSAN1 is Caused by the Accumulation of Two Neurotoxic Sphingolipids
  • Eichler et al. (2009) – Overexpression of WT SPT1 Lowers DSB Levels and Rescues Phenotype of HSAN1
  • McCampbell et al. (2005) – HSAN1 Mouse Model
  • Bejaoui et al. (2001) – SPTLC1 is Mutated in HSAN1
  • Bejaoui et al. (1999) – Genetic Linkage of HSAN1
  • Tocantins & Reimann (1939) – Perforating Ulcer

If you are diagnosed with HSAN1, Please register through this confidential form to be notified of upcoming research opportunities or clinical trials.

UMass Chan Medical School is cataloging cases of HSAN1 to better understand how to develop a cure.

Register Here

Search our posts:

  • 2022